Rockwell Medical, Inc. (RMTI)
NASDAQ: RMTI · Real-Time Price · USD
0.651
+0.000 (0.03%)
At close: Jun 26, 2026, 4:00 PM EDT
0.700
+0.049 (7.53%)
After-hours: Jun 26, 2026, 7:46 PM EDT
Rockwell Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Rockwell Medical stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 360.83% from the current stock price of 0.65.
Analyst Consensus: Buy
* Price targets were last updated on May 22, 2026.
Analyst Ratings
The average analyst rating for Rockwell Medical stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Nov '25 | Jan '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $2 | Buy | Reiterates | $2 | +207.22% | May 22, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $4 | Buy | Maintains | $4 | +514.44% | May 8, 2026 |
Financial Forecast
Revenue This Year
72.47M
from 69.26M
Increased by 4.64%
Revenue Next Year
78.29M
from 72.47M
Increased by 8.03%
EPS This Year
6.16
EPS Next Year
7.26
from 6.16
Increased by 17.86%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 72.5M | 80.5M | |
| Avg | 72.5M | 78.3M | |
| Low | 72.5M | 76.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.7% | 11.0% | |
| Avg | 4.6% | 8.0% | |
| Low | 4.6% | 5.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 6.16 | 7.26 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | 17.9% | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.